Walleye Capital
KPRX icon

Walleye Capital’s Kiora Pharmaceuticals KPRX Stock Holding History

Walleye Capital’s Portfolio KPRX Stock Details KPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-27,806
Closed -$162K – 5117
2023
Q2 		$162K Buy
+27,806
New +$583K ﹤0.01% 3208
2023
Q1 		– Sell
-9,256
Closed -$286K – 4167
2022
Q4 		$286K Buy
+9,256
New +$427K 0.01% 1826

Other funds holding KPRX

CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

Walleye Capital's KPRX Position: Q3 2023 in Review

Walleye Capital sold out of Kiora Pharmaceuticals (KPRX) in Q3 2023, closing a stake of 27,806 shares — an estimated $162K sold.

Walleye Capital first reported a position in KPRX in Q4 2022 and held it in 2 quarters. The position peaked at $286K in Q4 2022. 13 funds tracked by Wall St. Rank hold KPRX as of Q3 2023.

  • Walleye Capital reported no remaining Kiora Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Walleye Capital sold 27,806 Kiora Pharmaceuticals shares in Q3 2023, an estimated $162K.
  • Walleye Capital first reported a position in Kiora Pharmaceuticals in Q4 2022 and held it in 2 quarters.
  • Walleye Capital's Kiora Pharmaceuticals position peaked at $286K in Q4 2022.
  • 13 funds tracked by Wall St. Rank held Kiora Pharmaceuticals as of Q3 2023.

Based on Walleye Capital's 13F filing for Q3 2023, filed 14 Nov 2023.